证券代码：688338 证券简称：赛科希德 公告编号：2025-043 北京赛科希德科技股份有限公司 第四届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 表决内容：公司根据有关规定，编制了《北京赛科希德科技股份有限公司 2025 年第三季度报告》。全体监事认为：公司 2025 年第三季度报告内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 表决结果：3 票同意，0 票反对，0 票弃权。 2.审议通过《关于取消监事会及修订<公司章程>的议案》 表决内容：为全面贯彻落实法律法规及监管要求，进一步提升公司治理水平， 根据最新修订的法律、法规、规范性文件的规定，结合公司实际情况，同意公司 不再设置监事会，监事会职权由董事会审计委员会行使，公司现任监事职务相应 解除，公司《监事会议事规则》废止，同时对《公司章程》及部分制度进行修订。 本次取消监事会事项不会对公司治理、生产经营产生不利影响。在股东大会审议 通过之前，监事会及监事将继续按照有关法律、行政法规和《公司章程 ...

北京赛科希德科技股份有限公司 2025 年第三季度报告 证券代码：688338 证券简称：赛科希德 北京赛科希德科技股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | 年初至报告期 | 年初至报告期末 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 56,714,062.21 | -15.97 | 195,677, ...

证券代码：688338 证券简称：赛科希德 公告编号：2025-042 北京赛科希德科技股份有限公司高管减持股份计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 持股的基本情况 本次减持计划实施前，北京赛科希德科技股份有限公司（以下简称"公司"或"赛科希德"）高管裴燕彬先 生直接持有本公司股份140,400股,占公司总股本比例为0.13%。 上述股份均为无限售流通股，来源于公司首次公开发行前取得的股份以及公司实施资本公积转增股本取 得的股份。 ● 减持计划的实施结果情况 公司于2025年6月27日在上海证券交易所网站（www.sse.com.cn）披露了《北京赛科希德科技股份有限 公司高管减持股份计划公告》（公告编号：2025-030），公司高管裴燕彬先生因自身资金需求，拟通过 集中竞价等方式减持公司股份数量不超过35,000股, 不超过公司总股本比例的0.0330%，不超过其可减持 股份数的25%。 近日，公司收到高管裴燕彬先生出具的《关于减持结果的告知函》，截 ...

证券代码：688338 证券简称：赛科希德 公告编号：2025-042 北京赛科希德科技股份有限公司 高管减持股份计划时间届满暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 持股的基本情况 本次减持计划实施前，北京赛科希德科技股份有限公司（以下简称"公司" 或"赛科希德"）高管裴燕彬先生直接持有本公司股份 140,400 股,占公司总股本 比例为 0.13%。 一、减持主体减持前基本情况 | 股东名称 | 裴燕彬 | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | □是 | √否 | | | 董事、监事和高级管理人员 | √是 | □否 | | | 其他：无 | | | | 持股数量 | 140,400股 | | | | 持股比例 | 0.13% | | | | 当前持股股份来源 | IPO 前取得：108,000股 | | | | | 其他方式取得：32, ...

Group 1 - The company announced that its director and deputy general manager, Pei Yanbin, holds 140,400 shares, accounting for 0.13% of total shares [1] - Pei Yanbin had planned to reduce his holdings by up to 35,000 shares, representing 0.0330%, through centralized bidding and block trading from July 18 to October 18, 2025 [1] - As of October 18, 2025, the actual reduction was 0 shares, and the reduction plan has been terminated [1]

Core Viewpoint - The stock price of Saikohide has experienced fluctuations, with a current price of 25.62 CNY per share, reflecting a year-to-date increase of 7.34% but a recent decline over the past five and twenty trading days [1] Company Overview - Saikohide Technology Co., Ltd. was established on May 28, 2003, and listed on August 6, 2020. The company is based in Daxing District, Beijing, and specializes in the research, production, and sales of diagnostic instruments, reagents, and consumables in the field of thrombosis and hemostasis [1] - The revenue composition of Saikohide is as follows: reagents account for 53.71%, instruments for 25.40%, consumables for 20.58%, and other sources for 0.31% [1] Financial Performance - For the first half of 2025, Saikohide reported operating revenue of 139 million CNY, a year-on-year decrease of 12.62%. The net profit attributable to the parent company was approximately 48 million CNY, down 23.47% year-on-year [1] - As of June 30, the number of shareholders increased by 0.80% to 6,779, while the average circulating shares per person decreased by 0.80% to 15,657 shares [1] Dividend Information - Since its A-share listing, Saikohide has distributed a total of 136 million CNY in dividends, with 83.14 million CNY distributed over the past three years [2]

Group 1 - The company, Beijing Succeeder Technology Co., Ltd., will hold a performance briefing for the first half of 2025 on September 17, 2025, from 15:00 to 17:00 [1][2] - The briefing will be conducted in an online interactive format via the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions in advance from September 10 to September 16, 2025, and the company will address commonly asked questions during the session [2][3] Group 2 - Key participants in the briefing will include the company's General Manager Wang Hai, Deputy General Manager Ding Zhonghui, and other board members [2] - The contact information for inquiries includes the Board Office's phone number and email address [3]

北京赛科希德科技股份有限公司（以下简称"公司"）于 2025 年 8 月 22 日在 上海证券交易所网站（www.sse.com.cn）披露了《北京赛科希德科技股份有限公司 2025 年半年度报告》，为便于广大投资者更全面深入地了解公司 2025 年上半年度 的经营成果、财务状况、发展理念，公司计划参与 2025 年 09 月 17 日（星期三）1 5:00-17:00 由上交所主办的 2025 年半年度科创板医疗器械及医疗设备行业集体业 绩说明会，此次活动将采用网络文字互动的方式举行，投资者可登录上海证券交易 所上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、 说明会类型 投资者可于 2025 年 09 月 10 日（星期三）至 09 月 16 日（星期二）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 investor@ succeeder.com.cn 将需要了解和关注的问题提前提供给公司。公司将在说明会上 对投资者普遍关注的问题进行回答。 证券代码：688338 证券简称：赛科希德 公告编号：2025-041 北京赛科希德科技 ...

Core Viewpoint - The financial performance of Saikohide (688338) for the first half of 2025 shows a significant decline in revenue and net profit compared to the previous year, indicating challenges in the market and increased operational costs [1] Financial Performance Summary - Total revenue for the first half of 2025 was 139 million yuan, a decrease of 12.62% year-on-year [1] - Net profit attributable to shareholders was 47.99 million yuan, down 23.47% year-on-year [1] - Gross margin was 62.13%, a decrease of 1.37 percentage points year-on-year, while net margin was 34.51%, down 12.47 percentage points [1] - Total expenses (selling, administrative, and financial) accounted for 15.42% of total revenue, an increase of 47.39% year-on-year [1] - Earnings per share decreased to 0.46 yuan, down 22.03% year-on-year [1] Cash Flow and Asset Management - Cash flow from operating activities decreased by 28.55%, attributed to reduced sales revenue and slower collection of receivables [5] - The company increased its investment in structured deposits, leading to a 29.33% decrease in cash and cash equivalents [3] - The company reported a 150.08% increase in trading financial assets due to the same investment strategy [3] Revenue and Cost Analysis - Revenue decline of 12.62% was influenced by stricter management of inspection projects by medical institutions and reduced sales of reagents and consumables [5] - Operating costs also decreased by 10.57%, reflecting the overall drop in revenue [5] Debt and Liabilities - The company’s interest-bearing liabilities decreased by 14.87% [1] - Employee compensation liabilities decreased by 43.35% due to the payment of annual bonuses [4] Investment and Return Metrics - The company's return on invested capital (ROIC) was 5.49%, indicating average capital returns [8] - Historical data shows a median ROIC of 6.48% since the company’s listing, with the lowest recorded ROIC at 4.98% in 2021 [8] Overall Financial Health - The company maintains a healthy cash asset position, indicating good liquidity despite the decline in revenue and profit [9]

Core Viewpoint - The company plans to utilize idle self-owned funds for cash management, aiming to enhance the efficiency of fund usage and increase returns for shareholders while ensuring the safety of funds and normal business operations [4][58]. Group 1: Cash Management Overview - The company intends to use up to RMB 105,000 million of idle self-owned funds for cash management, focusing on high-security, liquid, and principal-protected cash management products [4][8]. - The cash management authorization period is set for 12 months from the board's approval date, allowing for rolling use of funds within the specified limit [4][54]. - The purpose of cash management is to improve the efficiency of idle funds and increase returns for the company and its shareholders [4][52]. Group 2: Financial Data and Fund Management - The company raised a total of RMB 102,774.42 million from its initial public offering, with a net amount of RMB 92,426.96 million after deducting issuance costs [50]. - All raised funds are managed in a dedicated account, and the company has established relevant regulatory agreements to ensure proper management and usage of the funds [19][50]. - As of June 30, 2025, the company has not used idle raised funds to supplement working capital [26]. Group 3: Risk Management and Control Measures - The company will select cash management products that are high in security and liquidity, with a maximum term of 12 months, and will not engage in non-principal-protected products [6][59]. - The finance department will monitor the operation and progress of cash management products, taking timely measures to mitigate risks if adverse factors are identified [11][60]. - The board's audit committee and independent directors have the authority to supervise and inspect the use of raised funds and cash management activities [11][60]. Group 4: Approval and Compliance - The board of directors and the supervisory board approved the cash management proposal during meetings held on August 20, 2025 [62][68]. - The proposal complies with relevant laws and regulations, ensuring that it does not affect the normal operation of fundraising investment projects or harm the interests of shareholders [63][65].